RTI International announced a follow-on investment and participation in a series B funding round for precision medical company PierianDx, the company said in a statement Thursday.

PierianDx was founded in 2014 out of Washington University in St. Louis and uses clinical genomics technology to advance cancer diagnostics and make therapeutics more accessible.

The $27 million funding round includes two new investors, ATW Partners and SJF Ventures, who join three existing investors.

“Advancements in the ability to harness knowledge from genomics has the potential to improve patient lives and advance the field of medicine,” said E. Wayne Holden, president and chief executive officer of RTI.

North Carolina-based RTI International is a research institute with operations in over 75 countries.